Mantle cell lymphoma: A biological and therapeutic paradigm

Leukemia and Lymphoma

Volumn 43, Issue 4, 2002, Pages 773-781

  Decaudin, Didier ^a  

^a INSTITUT CURIE   (France)

Author keywords

Chemotherapy; Lymphomogenesis; Mantle cell lymphoma; Therapeutic paradigm

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ATM PROTEIN; BLEOMYCIN; CD20 ANTIGEN; CHLORMETHINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GEMCITABINE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; ONCOPROTEIN; PACLITAXEL; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; PROTEIN BCL 1; PROTEIN CCND 1; PROTEIN P53; PROTEIN PRAD 1; PURINE DERIVATIVE; RITUXIMAB; TENIPOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CHROMOSOME 11Q; CHROMOSOME 14Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG RESPONSE; GENE LOSS; GENE MUTATION; GENETIC DISORDER; GENETIC RECOMBINATION; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LYMPH FOLLICLE; LYMPHOMOGENESIS; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

CELL CYCLE PROTEINS; CHROMOSOME ABERRATIONS; DNA-BINDING PROTEINS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 0036231124     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190290016881     Document Type: Article

References (116)

1. "Mantle cell lymphoma: A proposal for unification of morphologic, immunologic and molecular data"
2. "Malignant lymphomas of B-cell type"
3. "Histopathology of malignant lymphomas"
4. "Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma"
5. "Summary and description of a working formulation for clinical usage"
6. "A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group"
7. "Human B-cell development. II. Subpopulations in the human fetus"
8. "Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD 1 loci in centrocytic lymphoma"
9. "Mantle cell lymphoma"
10. "Molecular characterization of 11q deletion points to a pathogenic role of the ATM gene in mantle cell lymphoma"
11. "Patterns of survival in mantle cell lymphoma"
12. "Mantle cell lymphoma: Natural history defined in a serially biopsed population over a 20-year period"
13. "Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes"
14. "Clinical characteristics and response to chemotherapy of mantle cell lymphomas-results of a European survey"
15. "Mantle cell lymphoma-an entity comes of age"
16. "Mantle cell lymphoma: A clinicopathologic study of 80 cases"
17. "Mantle cell lymphomas: Characteristics, natural history and prognostic factors of 45 cases"
18. "Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors"
19. "Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients"
20. "Mantle cell lymphoma: A retrospective study of 121 cases"
21. "The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma"
22. "Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma"
23. "Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma"
24. "High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: A single center experience on 18 patients"
25. "Autologous stem cell transplantation for mantle cell lymphoma
26. "High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma no evidence for long-term remission"
27. "Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for aggressive mantle-cell lymphoma"
28. "High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors. A single center experience"
29. "Efficacy of autologous stem cell transplantation in mantle cell lymphoma: A 3-year follow-up study"
30. "Further evaluation of a sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma"
31. "Autologous hematopoietic stem cell transplantation for mantle cell lymphoma"
32. "On a new technique of human karyotype study"
33. "Break in the BCL-1 locus is closely associated with intermediate lymphocytic lymphoma subtype"
34. "Re-arrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: Analysis with multiple breakpoints probes"
35. "Detection of t(11;14)(q13;q32) using interphase cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia"
36. "Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas"
37. "Bcl-1 gene rearrangements in mantle cell lymphoma: A comprehensive analysis of 118 cases, including B-5-fixed tissue, by polymerase chain reaction and southern transfer analysis"
38. "Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas"
39. "Proliferative fraction, bcl-1 gene translocation, and p53 mutation status as markers in mantle cell lymphoma"
40. "Real-time 5′ → 3′ (exonuclease-based PCR assay for detection of the t(11;14)(q13;q32)"
41. "Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias"
42. "PRAD-1/cyclin D gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma"
43. "PRAD-1 gene overexpression in mantle cell lymphoma but not in other low grade B-cell lymphomas, including extranodal lymphoma"
44. "Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma"
45. "Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with or without rearrangement of the BCL-1/cyclin D1 gene"
46. "Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants"
47. "Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma"
48. "Secondary chromosome charges in mantle cell lymphoma"
49. "Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma"
50. "13q14 deletion in non-Hodgkin's lymphoma: Correlation with clinicopathologic features"
51. "p53 Overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32)"
52. "p53 Mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis"
53. "p53 Gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas"
54. "Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma"
55. "Proliferative fraction, bcl-1 translocation, and p53 mutation status as markers in mantle cell lymphoma"
56. "Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma"
57. "p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas"
58. "c-myc mRNA expression and genomic alternations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas"
59. "Expression of retinoblastoma gene product (pRB) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity"
60. "Expression of the retinoblastoma protein in low-grade B-cell lymphoma: Relationship to cyclin D1"
61. "Molecular characterization of deletion at 11q22.1-23.3 in mantle cell lymphoma"
62. "Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma"
63. "Mantle cell lymphoma is characterized by inactivation of the ATM gene"
64. "Ataxia telangiectasia gene mutations in leukaemia and lymphoma"
65. "Genomic organization of the ATM gene"
66. "A single ataxia telangiectasia gene with a product similar to PI-3 kinase"
67. "Splitting the ATM: Distinct repair and checkpoint defects in ataxia-telangiectasia"
68. "Enhanced phosphorylation of p53 by ATM in response to DNA damage"
69. "Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation"
70. "Interaction between ATM protein and c-Abl in response to DNA damage"
71. "Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma"
72. "Critical role for ATM in suppressing V(D)J recombination-driven thymic lymphoma"
73. "Mortality and cancer incidence in 263 patients with ataxia-telangiectasia"
74. "Incidence of cancer in 161 families affected by ataxia-telangiectasia"
75. "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia"
76. "Inactivation of the ATM gene in T-cell prolymphocytic leukemias"
77. "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia"
78. "11q Deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis"
79. "Is mantle cell lymphoma a sex-related disease?"
80. "CNS involvement in mantle-cell lymphoma"
81. "Central nervous system involvement in patients with mantle cell lymphoma"
82. "A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group Study"
83. "Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group"
84. "Mantle-cell lymphoma: A population-based clinical study"
85. "Treatment of mantle-cell lymphomas with the VAD+/ - Chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem cell transplantation"
86. "Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low grade non-Hodgkin's lymphoma"
87. "Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy"
88. "Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas"
89. "Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmocytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma"
90. "Fludarabine-based chemotherapy in untreated mantle cell lymphomas: An encouraging experience in 29 patients"
91. "Randomized trial of fludarabine versus fludarabine and idarubicine as frontline treatment in patients with indolent or mantle-cell lymphoma"
92. "NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma: A well-tolerated treatment with promising activity"
93. "Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse"
94. "Cladribine (2-chlorodeoxyadenosine, 2-CdA) plus mitoxantrone in the treatment of progressive advanced low-grade non-Hodgkin's and mantle cell lymphomas-preliminary results of a phase-II study"
95. "Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: Final report of a phase II trial"
96. "Gemcitabine for relapsed or resistant lymphoma"
97. "Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma"
98. "Dexa-BEAM: An effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma"
99. + selected blood cells for advanced mantle cell lymphoma: No evidence of long-term cure: A single centre experience"
100. "Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy"
101. "Allogeneic bone marrow transplantation for refractory mantle cell lymphoma"
102. "Patients with mantel-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation"
103. "Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: A case report and literature review on the in MCL"
104. "Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma"
105. "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing of refractory aggressive lymphoma: A multicenter phase II study"
106. "IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients"
107. "Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response"
108. "European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma"
109. "The effect of rituximab on patients with follicular and mantle-cell lymphoma
110. "Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell lymphoma: Evidence for a role of both chemotherapy and rituximab infusion"
111. "In vivo depletion of B-cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma"
112. "Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: Results of a phase II study"
113. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma"
114. "Phase I/II trial of IDEC-Y2B8 radio-immunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma"